Saratov JOURNAL of Medical and Scientific Research

Male face anatomy in the focus of aesthetic medicine

Year: 2016, volume 12 Issue: №3 Pages: 524-528
Heading: Dermatovenerology Article type: Review
Authors: Andreyeva A.V., Utz S.R.
Organization: Saratov State Medical University

The review presents research materials dealing with sexual dimorphism in the efficacy of botulinum toxin dosing. The differences in the structure of muscle and skeleton of male and female faces are presented. We have also considered the features of implementation of injection techniques, depending on gender.

1. Scherer M. Specific aspects of a combined approach to male face correction: botulinum toxin A and volumetric fillers. Journal of Cosmetic Dermatology 2016; 1: 1-9.
2. American Society for Plastic Surgery: 2011 statistics. Available from: (November 5, 2012)
3. Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46: 840-9
4. Yutskovskaya Y, Taran M. Gender peculiarities of botulinum toxin therapy in men. Cosmetic international 2013; 4: 38-43
5. Roginskiy YY, Levin MG. The basics of anthropology. The 3-d edition. Moscow: Vysschaya schkola, 1978; 528 p.
6. Janssen I, Hemsfield S, Wang Z, et al. Skeletal muscle mass and distribution in 468 men and women aged 18-88 years. JAppI Physiol 2000; 89: 81-8
7. Harii K, Kawashima M. A double-blind, randomized, placebo-controlled, two-dose comparative study of botulinum toxin type A for treating glabellar lines in Japanese subjects. Aesthetic Plast Surg 2008; 32: 724-30
8. Kawashima M, Harii K. An open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjects. Int J Dermatol 2009; 48: 768-76
9. Keaney T, Alster T. Botulinum Toxin in Men: Review of Relevant Anatomy and Clinical Trial Data Dermatol Surg 2013; 39: 1434-43
10. Golubev VL. The man's face from the point of view of its attractiveness (on materials of the lectures for cosmetologists). Vestnikesteticheskoj meditsiny 2014; 13 (2): 51-55
11. Moretti G, Ellis RA, Mescon H. Vascular patterns in the skin ofthe face. J Invest Dermatol 1959; 33: 103-12
12. Mayrovitz HN, Regan MB. Gender differences in facial skin blood perfusion during basal and heated conditions determined by laser Doppler flowmetry. Microvasc Res 1993; 45: 211-8
13. Montagna W, Ellis RA. Histology and cytochemistry of human skin. XIII: The blood supply ofthe hair follicle. J Nail Cancer Inst 1957; 19:451-63
14. De Maio M. Ethnic and Gender Considerations in the Use of Facial Injectables: Male Patients. Plast Reconstr Surg 2015; 136:40
15. De Maio M, Rzany B. Facial aesthetics in male patients. In: The Male Patient in Aesthetic Medicine. Berlin: Heidelberg; Springer-Verlag, 2009; p. 1-18
16. Paes EC, Teepen HJ, Koop WA, et al. Perioral wrinkles: histologic differences between men and women. Aesthet Surg J 2009; 29: 467-72
17. Ezure T, Yagi E, Kunizawa N, et al. Comparison of sagging at the cheek and lower eyelid between male and female faces. Skin ResTechnol 2011; 17: 510-5
18. Sjostrom L, Smith U, Krotkiewski M, et al. Cellularity in different regions of adipose tissue in young men and women. Metabolism 1972; 21: 1143-53
19. Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placeboin patients with crow's feet. J Am Acad Dermatol 2002; 47: 834-40
20. Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-62
21. Ascher B, Zakine B, Kestemont P, et al. A multicenter, randomized, double-blind, placebo-controlled study of efficacy and safety of 3 doses of botulinum toxin A in the treatment of glabellar lines. J Am Acad Dermatol 2004; 51: 223-33
22. Rzany B, Ascher B, Fratila A, et al. Efficacy and safety of 3- and 5-injection patterns (30 and 50 U) of botulinum toxin A (Dysport) for the treatment of wrinkles in the glabella and the central forehead region. Arch Dermatol 2006; 142: 320-6
23. Monheit G, Carruthers A, Brandt F. A randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: determination of optimal dose. Dermatol Surg 2007; 33 (1 Spec No.): S51-9
24. Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35: 1478-86
25. Brandt F, Swanson N, Baumann L, et al. Randomized, placebo-controlled study of a new botulinum toxin type a for treatment of glabellar lines: efficacy and safety. Dermatol Surg 2009; 35: 1893-901
26. Kane MAC, Brandt F, Rohrich RJ, et al. Evaluation of variable-dose treatment with a new US botulinum toxin type A (Dysport) for correction of moderate to severe glabellar lines: results from a phase 3, randomized, double-blind, placebo-controlled study. Plast Reconstr Surg 2009; 124: 1619-29
27. Rubin MG, Dover JS, Glogau RG, et al. The efficacy and safety of a new U. S. botulinum toxin type A in there treatment of glabellar lines following open-label treatment. J Drugs Dermatol 2009; 8: 439-44
28. Moy R, Maas C, Monheit G, et al. Long-term safety and efficacy of a new botulinum toxin type A in treating glabellar lines. Arch Facial Plast Surg 2009; 11: 77-83
29. Imhof M, Kuhne U. A phase III study of incobotulinum toxin A in the treatment of glabellar frown lines. J Clin Aesthet Dermatol 2011; 4: 28-34.

2016_03-1_524-528.pdf415.01 KB

No votes yet